ESMO

No articles in this language here yet. Showing English.

1. 22.10.26

   Moderna melanoma vaccine data surface early; shares fall 17.6%

   The Phase 3 INTerpath-001 results were positive, but the 42% reduction came in below the 49% seen in the earlier Phase 2b study, though the trials are not directly comparable. Full data are due at ESMO in Madrid on 24 October.

   FIN · 6 MIN